ZBIO
Zenas BioPharma, Inc.Marquee-fund ownership over time
This quarter's activity
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors re-entered | Q4 2024(8Q snapshot) | 6Q | $19 | $17 | -10% |
| Two Sigma Investments re-entered | Q4 2024(8Q snapshot) | 6Q | $19 | $17 | -10% |
| Millennium Management re-entered | Q4 2024(8Q snapshot) | 6Q | $19 | $17 | -10% |
| AQR Capital Management | Q3 2025(8Q snapshot) | 3Q | $17 | $17 | +1% |
| D.E. Shaw | Q2 2026(8Q snapshot) | 1Q | $0.00 | $17 | — |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Point72 Asset Management 2× in & out | Q1 2026 | Q2 2026 | → $18 | -31% |
| Renaissance Technologies | Q1 2025 | Q2 2025 | → $8.68 | +22% |
| Soros Fund Management | Q4 2024 | Q1 2025 | → $6.97 | -63% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Zenas BioPharma, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 18, 2026 — the most recent Form 4 on file — not from today.
- Form 40001104659-26-063362May 18, 2026
- Form 40001104659-26-051889Apr 29, 2026
- Form 40001104659-26-039240Apr 2, 2026
- Form 40001104659-26-038546Apr 1, 2026
- Form 40001104659-26-038031Mar 31, 2026
- Form 40001104659-26-037865Mar 31, 2026
- Form 40001104659-26-015387Feb 13, 2026
- Form 40001104659-26-015342Feb 13, 2026
- Form 40001104659-26-009756Feb 3, 2026
- Form 40001104659-26-002589Jan 9, 2026
- Form 40001193125-25-239158Oct 14, 2025
- Form 40001193125-25-239153Oct 14, 2025
- Form 40001193125-25-238326Oct 14, 2025
- Form 40001104659-25-098413Oct 9, 2025
- Form 40001104659-25-098362Oct 9, 2025
Fundamentals
XBRL · Zenas BioPharma, Inc.Annual figures sourced directly from Zenas BioPharma, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Zenas BioPharma, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 13, 2026
- 8-KFORM 8-KMay 13, 2026
- 8-KFORM 8-KMar 31, 2026
- DEF 14AProxy statementMar 16, 2026
- 10-KAnnual reportMar 16, 2026
- 8-KFORM 8-KMar 16, 2026
- 8-KFORM 8-KFeb 13, 2026
- 8-KFORM 8-KJan 5, 2026
- 8-KFORM 8-KDec 15, 2025
- 10-QQuarterly reportNov 12, 2025
- 8-KFORM 8-KNov 12, 2025
- 8-KFORM 8-KOct 27, 2025
- 8-KFORM 8-KOct 8, 2025
- 8-KFORM 8-KSep 2, 2025
- 10-QQuarterly reportAug 12, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q2 2026 | open | $0.00 | — | +0% |
| D.E. Shaw | Q2 2026 | open | $0.00 | — | +0% |
| Millennium Management | Q2 2026 | open | $0.00 | — | +0% |
| Citadel Advisors | Q1 2026 | open | $27 | $17 | -37% |
| Point72 Asset Management | Q1 2026 | Q2 2026 | $27 | $18 | -31% |
| Millennium Management | Q4 2025 | open | $35 | $17 | -52% |
| Citadel Advisors | Q3 2025 | Q4 2025 | $17 | $35 | +109% |
| Two Sigma Investments | Q3 2025 | open | $17 | $17 | +1% |
| AQR Capital Management | Q3 2025 | open | $17 | $17 | +1% |
| Renaissance Technologies | Q1 2025 | Q2 2025 | $7.14 | $8.68 | +22% |
| Citadel Advisors | Q4 2024 | Q2 2025 | $19 | $9.74 | -48% |
| Soros Fund Management | Q4 2024 | Q1 2025 | $19 | $6.97 | -63% |
| Two Sigma Investments | Q4 2024 | Q2 2025 | $19 | $9.74 | -48% |
| Millennium Management | Q4 2024 | Q2 2025 | $19 | $9.74 | -48% |
| Point72 Asset Management | Q4 2024 | Q1 2025 | $19 | $6.97 | -63% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.